Get the Stockscreener App
0.729
0.41%
-0.003
Oncolytics Biotech Inc stock is traded at $0.729, with a volume of 431.87K.
It is down -0.41% in the last 24 hours and down -20.22% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.732
Open:
$0.7346
24h Volume:
431.87K
Relative Volume:
0.39
Market Cap:
$56.19M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-2.7561
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-7.42%
1M Performance:
-20.22%
6M Performance:
-29.90%
1Y Performance:
-38.74%
1-Day Range:
$0.716
$0.746
1-Week Range:
$0.7102
$0.775
52-Week Range:
$0.7101
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.729 | 56.19M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech (TSE:ONC) Reaches New 52-Week LowHere's What Happened - MarketBeat
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - The Globe and Mail
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium - Barchart
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastroin - GuruFocus.com
Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers At 2025 Asco GI Symposium - Marketscreener.com
Oncology Experts Predict 2025 Will Be a Year of Breakthroughs in Treatment and Prevention - Baystreet.ca
USA News Group: Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - finanznachrichten.de
Guardant Health Inc (GH-Q) QuotePress Release - The Globe and Mail
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus - GlobeNewswire
Oncolytics Biotech Presents Promising Cancer Treatment Data - TipRanks
German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial - MSN
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech - The Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA - openPR
Oncolytics Biotech (TSE:ONC) Shares Down 3.4%What's Next? - MarketBeat
Oncolytics Biotech Inc. Announces Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - Marketscreener.com
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Stocks In Play: Oncolytics Biotech Inc - Barchart
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Lelezard
Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - Barchart
Oncolytics Biotech (TSE:ONC) Trading Down 3.4%Time to Sell? - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Regulatory Approval Clears Path for Oncolytics Biotech® to Advan - GuruFocus.com
Oncolytics Biotech Advances Pancreatic Cancer Treatment with Regulatory Approval - TipRanks
Oncolytics Biotech (TSE:ONC) Share Price Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
Oncolytics Biotech (TSE:ONC) Shares Pass Below 200-Day Moving Average – Here’s Why - Defense World
A Data-Based Look At Oncolytics Biotech, Inc (ONCY) - Stocks Register
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus.com
Suncor Energy Inc (SU-N) QuotePress Release - The Globe and Mail
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 3.2% – Still a Buy? - Defense World
Oncolytics Biotech (TSE:ONC) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Trading Up 3.2%What's Next? - MarketBeat
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely? - Yahoo Finance
Oncolytics Biotech (TSE:ONC) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Oncolytics Biotech (TSE:ONC) Stock Passes Above 200 Day Moving Average – Here’s Why - Defense World
Oncology In Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Barchart
The Immunotherapy Boom: What It Means For The Future Of Cancer Treatment - MENAFN.COM
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment - Baystreet.ca
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook - GlobeNewswire
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data - Barchart
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options - Informazione.it
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses - Lelezard
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.95%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):